Higher levels of physical activity are linked to better disease outcomes and quality of life in people with axial spondyloarthritis (axSpA), including ankylosing spondylitis (AS), according to a recent study. “Patients with axSpA should be especially encouraged to exercise, as it is particularly beneficial for disease-related outcomes,” researchers wrote.
Blood biomarkers, such as elevated levels of certain white blood cells and other markers of inflammation, may help doctors predict who is likely to develop ankylosing spondylitis and help clinicians determine the degree of disease activity, a study found. There are “basic, easily accessible, and affordable indicators that can be…
Two-thirds of adults with spondyloarthritis (SpA), a family of related inflammatory conditions that includes ankylosing spondylitis (AS), reported at least two symptoms related to the gastrointestinal (GI) tract, according to the findings of a new study. About half of SpA patients also reported depression, which significantly correlated with increased disease activity, greater functional…
The Axial Spondyloarthritis International Foundation (ASIF) is encouraging members of the ankylosing spondylitis community to wear orange shoelaces as part of this Saturday’s “Lace Up for axSpA” annual World AS Day. Held each year on the first Saturday of May, the event is designed to raise awareness…
A version of Purified Cortrophin Gel (repository corticotropin injection) that comes in a prefilled syringe has been approved by the U.S. Food and Drug Administration (FDA) for treating ankylosing spondylitis (AS) and other inflammatory diseases. The injectable treatment from Ani Pharmaceuticals initially was approved in…
The U.S. Food and Drug Administration (FDA) has agreed to review an application seeking approval of AVT05, a proposed biosimilar for Simponi (golimumab), which is an approved treatment for ankylosing spondylitis. Developers Alvotech and Teva Pharmaceuticals said this marks the first time that the FDA has…
Screening is ongoing for adults with active axial spondyloarthritis or axSpA, including ankylosing spondylitis, for a Phase 2 clinical trial in Germany that’s testing sonelokimab — a nanobody in the pipeline of Moonlake Immunotherapeutics for inflammatory diseases of the skin and joints. The goal of the open-label study,…
Levels of multiple immune cell types were found to be altered in the blood of people with ankylosing spondylitis (AS) relative to healthy individuals in a recent study. Immune imbalances correlated with measures of disease severity and, in some cases, a balance was restored over time among patients on…
Most adults with active ankylosing spondylitis or non-radiographic axial spondyloarthritis who achieved low or no disease activity after four months on the recently approved Bimzelx (bimekizumab-bkzx) maintained their clinical response over at least two years. Two-year data from the Phase 3 clinical trials BE MOBILE 1 (NCT03928704)…
People with ankylosing spondylitis (AS) face difficulties in diagnosis and treatment, must deal with the debilitating effects of disease symptoms, and handle adjustments in social roles, often while contending with a lack of understanding and support — all factors that add to an increased disease burden for patients. That’s…
Get regular updates to your inbox.